LTBR

Business Context and Reporting Period

Company: LIGHTBRIDGE Corp (LTBR)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Lightbridge is a pre-revenue nuclear fuel technology company developing proprietary metallic fuel (Lightbridge Fuel™) for water-cooled reactors. The technology aims to improve reactor safety, economics, and proliferation resistance. The company is currently in the research and development (R&D) phase, conducting irradiation testing at the Idaho National Laboratory (INL) and developing fabrication processes. It has no commercial revenue and relies on equity financing to fund operations.

Key Financial Metrics

Note: The company has no debt or lines of credit. Liquidity is derived from cash reserves and At-The-Market (ATM) equity offerings.

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss increased by 66% (from $11.8M to $19.6M) driven by a 77% increase in total operating expenses.
• R&D Expense Surge: Research and development expenses doubled (100% increase) to $9.2 million. Key drivers included:
  • $1.2 million increase in INL project labor costs due to new agreement modifications.
  • $1.9 million increase in IT expenses, primarily for the purchase of a high-performance computer (HPC) and related software for nuclear modeling.
  • $1.8 million increase in allocated employee compensation and stock-based compensation.
• G&A Expense Growth: General and administrative expenses rose 65% to $14.0 million, largely due to increased stock-based compensation ($2.4M increase) and professional/consulting services ($2.1M increase).
• Capital Raise: The company raised approximately $176.0 million in net proceeds from the sale of ~12.6 million shares via ATM programs in 2025, compared to $21.4 million in 2024. This resulted in a cash balance increase of $161.9 million.

Guidance, Outlook, and Risks

Outlook and Milestones

• Commercialization Timeline: Management expects to begin demonstration of lead test rods/assemblies in commercial reactors in the mid-2030s, with initial purchase orders for fuel reload batches expected in the late 2030s.
• Recent Milestones:
  • Commenced irradiation testing of enriched uranium-zirconium alloy fuel material coupon samples at INL in November 2025.
  • Entered into a Memorandum of Understanding (MOU) with Oklo, Inc. to evaluate co-locating a fuel fabrication facility.
  • Extended Strategic Partnership Project Agreement (SPPA) with INL from 7 to 12 years.
• Liquidity: Management believes current cash resources ($201.9M) are sufficient to fund operations for at least the next 12 months. Long-term funding will require additional equity, strategic partnerships, or government grants.

Risks and Contingencies

• Capital Requirements: Significant additional capital is required to reach commercialization. Failure to raise funds could force a reduction or cessation of R&D.
• Regulatory and Testing Delays: Commercialization depends on NRC approval, access to test reactor loops (specifically at INL), and successful demonstration of fuel performance. Delays in these areas could extend timelines significantly.
• Supply Chain Constraints: The technology requires High-Assay Low-Enriched Uranium (HALEU) in metallic form, for which commercial supply infrastructure is currently limited or non-existent in the U.S.
• Competition: Potential competition from Accident Tolerant Fuels (ATF) that may achieve similar cycle length extensions or power uprates.
• Intellectual Property: Risks related to maintaining patent rights in Russia due to sanctions and potential challenges to IP ownership by the U.S. DOE.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $14.3M annual operating cash burn against the $201.9M cash balance to confirm the 12-month runway.
• ATM Capacity: Confirm the remaining capacity under the Jefferies ATM agreement ($142.1M available as of Dec 31, 2025) and monitor stock price volatility which impacts execution.
• INL Agreement Costs: Monitor the $14.1M remaining reimbursable obligation to Battelle Energy Alliance (BEA) and potential cost overruns noted by INL regarding resource constraints.
• Testing Schedule: Track the progress of the irradiation testing at INL (ATR) and the timeline for post-irradiation examination (anticipated late 2026/early 2027).
• Stock-Based Compensation: Review the impact of performance-based restricted stock awards (PSAs) on future expenses, particularly the $13.3M grant date fair value of outstanding tranches tied to milestones through 2028.